MedPath

ORLANDO IMMUNOLOGY CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
http://www.oicorlando.com/

Clinical Trials

3

Active:0
Completed:1

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)

A Pharmacist-run PrEP Program for Women

Terminated
Conditions
HIV Prevention
Interventions
Drug: LA-CAB
Drug: TDF/FTC
First Posted Date
2023-03-06
Last Posted Date
2025-02-14
Lead Sponsor
Orlando Immunology Center
Target Recruit Count
2
Registration Number
NCT05755204
Locations
🇺🇸

Orlando Immunology Center, Orlando, Florida, United States

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

Phase 4
Recruiting
Conditions
HIV-1-infection
Interventions
First Posted Date
2022-02-02
Last Posted Date
2023-11-03
Lead Sponsor
Orlando Immunology Center
Target Recruit Count
50
Registration Number
NCT05220358
Locations
🇺🇸

Orlando Immunology Center, Orlando, Florida, United States

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

Completed
Conditions
HIV Infections
First Posted Date
2006-04-07
Last Posted Date
2008-05-22
Lead Sponsor
Orlando Immunology Center
Target Recruit Count
20
Registration Number
NCT00312169
Locations
🇺🇸

Special Services Adult HIV Clinic, Fresno, California, United States

🇺🇸

AltaMed Health Services Corporation, Los Angelos, California, United States

🇺🇸

Shared Medical Research Foundation, Tarzana, California, United States

and more 8 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.